EX-99.1
2
ex99_1.htm
EXHIBIT 99.1
Exhibit 99.1
Exhibit
99.1
For
Immediate Release
For
more information:
Contact: Michael
Doherty
Phone: 949-673-1907
Email: mdoherty@trestlecorp.com
TRESTLE
HOLDINGS FINALIZES ACQUISITION OF INTERSCOPE TECHNOLOGIES
Dr.
Michael Becich joins Trestle's Board of Directors
IRVINE,
Calif., March 14, 2005
-
Trestle Holdings, Inc. (OTCBB:TLHO), a
supplier of digital imaging systems and services for pathology, drug safety and
discovery, today announced that it has consummated its previously announced
acquisition of the assets of InterScope Technologies Inc. The acquisition price
was 377,838 shares of Trestle common stock, the reimbursement of certain
InterScope expenses and the assumption of certain InterScope contracts. Trestle
also hired certain InterScope personnel.
Commenting
of the acquisition, Maurizio Vecchione, Trestle's CEO, said, "This acquisition
provides us with software components and other technologies that could
accelerate development of our services platform, specifically in the area of
improved workflow for clinical and biopharmaceutical tissue
informatics".
Late last
year, Trestle announced the launch of a digital pathology service platform for
pharmaceutical, biotechnology drug safety, discovery and healthcare
organizations. This service is expected to offer managed data capture, online
data management and virtual microscopy applications. "We believe the additional
technologies from InterScope should help expand our service offering into the
area of data mining of information in support of drug safety, drug discovery and
clinical applications", Vecchione added.
Concurrent
with the closing of the transaction, Dr. Michael Becich, InterScope's founder
and chairman of its Medical Advisory Board, was appointed to Trestle's Board of
Directors. Dr. Becich is currently director of the Center for Pathology
Informatics at the University of Pittsburgh Medical School; vice chairman for
pathology informatics for the UPMC Health System; director of the Benedum
Oncology Informatics Center at University of Pittsburgh Cancer Institute; as
well as professor of pathology at University of Pittsburgh School of
Medicine.
Trestle's
chairman, Michael Doherty, commented, "Dr. Becich brings us a lifetime of
knowledge and experience in the science of pathology, combined with his vision
as one of the pioneers of tissue imaging and informatics. This knowledge as well
as his background as an entrepreneur is expected to be invaluable to the
Company."
About
Trestle Holdings Inc.
Trestle
Holdings, Inc. develops and sells digital imaging and telemedicine applications
to the life sciences markets. The Company's products link dispersed users with
each other, information databases, and analytical tools. This improved
integration drives cost savings and process efficiencies, enables improved
pre-clinical and clinical phases of research and development for new drugs, and
enhances patient care.
Trestle's
digital imaging products have the potential to transform the pathologist work
environment by capturing digital images of tissue samples and enabling the
sharing, archiving, and analysis of these images. The Company's live microscopy
products allow multiple physicians and scientists to remotely view, navigate,
and share high fidelity microscope images at sub-micron resolution over standard
Internet connections in real time. The Company's slide scanning and imaging
products perform high-speed whole glass slide digitization for virtual
microscopy applications. Trestle's slide scanning products facilitate image
analysis, data management, digital workflow and data association applications
for clinical and research customers.
Telemedicine
enables the remote delivery of patient care using integrated health information
systems and telecommunications technologies. Trestle's integrated telemedicine
products allow scientists, physicians and other medical professionals around the
world to service more patients. Trestle's telemedicine products use proprietary
software and standard computer and medical hardware to facilitate remote
examination, diagnosis, and treatment of patients through real time integration
of voice, video, medical devices, and patient data.
-- more
--
This
press release contains statements about expected future events that are
forward-looking and subject to risks and uncertainties. For these statements, we
claim the safe harbor for "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Factors that could cause
actual results to differ and vary materially from expectations include, but are
not limited to, our ability to expand our product offerings, including our
service platform, and any transition to new products, product quality and
availability, timing and costs of integrating the InterScope acquisition,
liabilities assumed in the InterScope transaction, any change in business
conditions, changes in our sales strategy and product development plans,
competitive pricing pressures, continued market acceptance of our products, name
recognition of our products, delays in the development of new technology,
intellectual property and proprietary rights may not be valid or infringe the
rights of others, changes in customer buying pattern issues, one-time events and
other important factors disclosed previously and from time to time in our
filings with the Securities and Exchange Commission. These cautionary statements
by us should not be construed as exhaustive or as any admission regarding the
adequacy of disclosures made by us. We cannot always predict or determine after
the fact what factors would cause actual results to differ materially from those
indicated by the forward-looking statements or other statements. In addition,
readers are urged to consider statements that include the terms "believes,"
"belief", "expects", "plans", "objectives", "anticipates", "intends", "targets,"
"projections", or the like to be uncertain and forward-looking. All cautionary
statements should be read as being applicable to all forward-looking statements
wherever they appear. We do not undertake any obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
###

EX - 99 . 1 2 ex99 _ 1 . htm EXHIBIT 99 . 1 Exhibit 99 . 1 Exhibit 99 . 1 For Immediate Release For more information : Contact : Michael Doherty Phone : 949 - 673 - 1907 Email : mdoherty@trestlecorp.com TRESTLE HOLDINGS FINALIZES ACQUISITION OF INTERSCOPE TECHNOLOGIES Dr . Michael Becich joins Trestle 's Board of Directors IRVINE , Calif . , March 14 , 2005 - Trestle Holdings , Inc . ( OTCBB : TLHO ) , a supplier of digital imaging systems and services for pathology , drug safety and discovery , today announced that it has consummated its previously announced acquisition of the assets of InterScope Technologies Inc . The acquisition price was 377,838 shares of Trestle common stock , the reimbursement of certain InterScope expenses and the assumption of certain InterScope contracts . Trestle also hired certain InterScope personnel . Commenting of the acquisition , Maurizio Vecchione , Trestle 's CEO , said , " This acquisition provides us with software components and other technologies that could accelerate development of our services platform , specifically in the area of improved workflow for clinical and biopharmaceutical tissue informatics " . Late last year , Trestle announced the launch of a digital pathology service platform for pharmaceutical , biotechnology drug safety , discovery and healthcare organizations . This service is expected to offer managed data capture , online data management and virtual microscopy applications . " We believe the additional technologies from InterScope should help expand our service offering into the area of data mining of information in support of drug safety , drug discovery and clinical applications " , Vecchione added . Concurrent with the closing of the transaction , Dr . Michael Becich , InterScope 's founder and chairman of its Medical Advisory Board , was appointed to Trestle 's Board of Directors . Dr . Becich is currently director of the Center for Pathology Informatics at the University of Pittsburgh Medical School ; vice chairman for pathology informatics for the UPMC Health System ; director of the Benedum Oncology Informatics Center at University of Pittsburgh Cancer Institute ; as well as professor of pathology at University of Pittsburgh School of Medicine . Trestle 's chairman , Michael Doherty , commented , " Dr . Becich brings us a lifetime of knowledge and experience in the science of pathology , combined with his vision as one of the pioneers of tissue imaging and informatics . This knowledge as well as his background as an entrepreneur is expected to be invaluable to the Company . " About Trestle Holdings Inc . Trestle Holdings , Inc . develops and sells digital imaging and telemedicine applications to the life sciences markets . The Company 's products link dispersed users with each other , information databases , and analytical tools . This improved integration drives cost savings and process efficiencies , enables improved pre - clinical and clinical phases of research and development for new drugs , and enhances patient care . Trestle 's digital imaging products have the potential to transform the pathologist work environment by capturing digital images of tissue samples and enabling the sharing , archiving , and analysis of these images . The Company ' s live microscopy products allow multiple physicians and scientists to remotely view , navigate , and share high fidelity microscope images at sub - micron resolution over standard Internet connections in real time . The Company 's slide scanning and imaging products perform high - speed whole glass slide digitization for virtual microscopy applications . Trestle 's slide scanning products facilitate image analysis , data management , digital workflow and data association applications for clinical and research customers . Telemedicine enables the remote delivery of patient care using integrated health information systems and telecommunications technologies . Trestle 's integrated telemedicine products allow scientists , physicians and other medical professionals around the world to service more patients . Trestle 's telemedicine products use proprietary software and standard computer and medical hardware to facilitate remote examination , diagnosis , and treatment of patients through real time integration of voice , video , medical devices , and patient data . -- more -- This press release contains statements about expected future events that are forward - looking and subject to risks and uncertainties . For these statements , we claim the safe harbor for " forward - looking statements " within the meaning of the Private Securities Litigation Reform Act of 1995 . Factors that could cause actual results to differ and vary materially from expectations include , but are not limited to , our ability to expand our product offerings , including our service platform , and any transition to new products , product quality and availability , timing and costs of integrating the InterScope acquisition , liabilities assumed in the InterScope transaction , any change in business conditions , changes in our sales strategy and product development plans , competitive pricing pressures , continued market acceptance of our products , name recognition of our products , delays in the development of new technology , intellectual property and proprietary rights may not be valid or infringe the rights of others , changes in customer buying pattern issues , one - time events and other important factors disclosed previously and from time to time in our filings with the Securities and Exchange Commission . These cautionary statements by us should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by us . We can not always predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward - looking statements or other statements . In addition , readers are urged to consider statements that include the terms " believes , " " belief " , " expects " , " plans " , " objectives " , " anticipates " , " intends " , " targets , " " projections " , or the like to be uncertain and forward - looking . All cautionary statements should be read as being applicable to all forward - looking statements wherever they appear . We do not undertake any obligation to publicly update or revise any forward - looking statements , whether as a result of new information , future events or otherwise . # # #